List of bibliographic references
Number of relevant bibliographic references: 28.
[0-20] [
0 - 20][
0 - 28][
20-27][
20-40]
Ident. | Authors (with country if any) | Title |
---|
000007 (2011) |
Jose Luis L Pez-Send N [Espagne] ; Ana Royuela [Espagne] ; Patricia Trigo [Espagne] ; Michael Orth [Allemagne] ; Herwig Lange [Allemagne] ; Ralf Reilmann [Allemagne] ; Jennifer Keylock [Royaume-Uni] ; Hugh Rickards [Royaume-Uni] ; Silvia Piacentini [Italie] ; Ferdinando Squitieri [Italie] ; Bernhard Landwehrmeyer [Allemagne] ; Marie-Noelle Witjes-Ane [Pays-Bas] ; Caroline. K. Jurgens [Pays-Bas] ; Raymund. A. C. Roos [Pays-Bas] ; Victor Abraira [Espagne] ; Justo. G. De Yébenes [Espagne] | What is the impact of education on Huntington's disease? |
000064 (2011) |
Sean S. O'Sullivan [Royaume-Uni] ; Mary Johnson [Royaume-Uni] ; David R. Williams [Australie] ; Tamas Revesz [Royaume-Uni] ; Janice L. Holton [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] ; Elaine K. Perry [Royaume-Uni] | The effect of drug treatment on neurogenesis in Parkinson's disease |
000400 (2011) |
Peter Jenner [Royaume-Uni] ; J. William Langston [États-Unis] | Explaining ADAGIO: A critical review of the biological basis for the clinical effects of rasagiline |
000407 (2011) |
Martin Köllensperger [Autriche] ; Florian Krismer [Autriche] ; Anton Pallua [Autriche] ; Nadia Stefanova [Autriche] ; Werner Poewe [Autriche] ; Gregor K. Wenning [Autriche] | Erythropoietin is neuroprotective in a transgenic mouse model of multiple system atrophy |
000503 (2011) |
Robert D. Altman [Canada] ; Anthony E. Lang [Canada] ; Ronald B. Postuma [Canada] | Caffeine in Parkinson's disease: A pilot open‐label, dose‐escalation study |
000579 (2011) |
Anthony E. Lang [Canada] | A critical appraisal of the premotor symptoms of Parkinson's disease: Potential usefulness in early diagnosis and design of neuroprotective trials |
000742 (2010) |
Anthony H. V. Schapira [Royaume-Uni] ; Stefan Albrecht [Allemagne] ; Paolo Barone [Italie] ; Cynthia L. Comella [États-Unis] ; Michael P. Mcdermott [États-Unis] ; Yoshikuni Mizuno [Japon] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; Kenneth Marek [États-Unis] | Rationale for delayed‐start study of pramipexole in Parkinson's disease: The PROUD study |
000B69 (2010) |
Barry J. Snow [Nouvelle-Zélande] ; Fiona L. Rolfe [Nouvelle-Zélande] ; Michelle M. Lockhart [Nouvelle-Zélande] ; Christopher M. Frampton [Nouvelle-Zélande] ; John D. O'Sullivan [Australie] ; Victor Fung [Australie] ; Robin A. J. Smith [Nouvelle-Zélande] ; Michael P. Murphy [Royaume-Uni] ; Kenneth M. Taylor [Nouvelle-Zélande] | A double‐blind, placebo‐controlled study to assess the mitochondria‐targeted antioxidant MitoQ as a disease‐modifying therapy in Parkinson's disease |
000D00 (2009) |
Robert A. Hauser [États-Unis] ; Kelly E. Lyons [États-Unis] ; Terry Mcclain [États-Unis] ; Summer Carter [États-Unis] ; David Perlmutter [États-Unis] | Randomized, double‐blind, pilot evaluation of intravenous glutathione in Parkinson's disease |
000D88 (2009) |
Robert G. Hart [États-Unis] ; Lesly A. Pearce [États-Unis] ; Bernard M. Ravina [États-Unis] ; Toby C. Yaltho [États-Unis] ; John R. Marler [États-Unis] | Neuroprotection trials in Parkinson's disease: Systematic review |
000E27 (2009) |
Robert A. Hauser [États-Unis] ; Mark F. Lew [États-Unis] ; Howard I. Hurtig [États-Unis] ; William G. Ondo [États-Unis] ; Joanne Wojcieszek [États-Unis] ; Cheryl J. Fitzer-Attas [Israël] | Long‐term outcome of early versus delayed rasagiline treatment in early Parkinson's disease |
001103 (2008) |
Ilana Schlesinger [Israël] ; Naomi Schlesinger [États-Unis] | Uric acid in Parkinson's disease |
001149 (2008) |
Anthony H. V. Schapira [Royaume-Uni] | The clinical relevance of levodopa toxicity in the treatment of Parkinson's disease |
001290 (2008) |
Maryka Quik [États-Unis] ; Kathryn O'Leary [États-Unis] ; Caroline M. Tanner [États-Unis] | Nicotine and Parkinson's disease: Implications for therapy |
001553 (2008) |
Carl E. Clarke [Royaume-Uni] | Are delayed‐start design trials to show neuroprotection in Parkinson's disease fundamentally flawed? |
001586 (2008) |
C. Warren Olanow [États-Unis] ; Robert A. Hauser [États-Unis] ; Joseph Jankovic [États-Unis] ; William Langston [États-Unis] ; Anthony Lang [Canada] ; Werner Poewe [Autriche] ; Eduardo Tolosa [Espagne] ; Fabrizio Stocchi [Italie] ; Eldad Melamed [Israël] ; Eli Eyal [Israël] ; Olivier Rascol [France] | A randomized, double‐blind, placebo‐controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): Rationale, design, and baseline characteristics |
001832 (2007) |
Anna L. Bartels [Pays-Bas] ; Klaus L. Leenders [Pays-Bas] | Neuroinflammation in the pathophysiology of Parkinson's disease: Evidence from animal models to human in vivo studies with [11C]‐PK11195 PET |
001944 (2007) |
Anthony H. V. Schapira [Royaume-Uni] | Future directions in the treatment of Parkinson's disease |
001B38 (2007) |
Kjell Fuxe [Suède] ; Daniel Marcellino [Suède] ; Susanna Genedani [Italie] ; Luigi Agnati [Italie] | Adenosine A2A receptors, dopamine D2 receptors and their interactions in Parkinson's disease |
002255 (2005) |
Robert M. Silva [États-Unis] ; Chia-Yi Kuan [États-Unis] ; Pasko Rakic [États-Unis] ; Robert E. Burke [États-Unis] | Mixed lineage kinase–c‐jun N‐terminal kinase signaling pathway: A new therapeutic target in Parkinson's disease |
002533 (2004) |
Tomás González-Hernández [Espagne] ; Pedro Barroso-Chinea [Espagne] ; Manuel Rodríguez [Espagne] | Response of the GABAergic and dopaminergic mesostriatal projections to the lesion of the contralateral dopaminergic mesostriatal pathway in the rat |
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Checkpoint
HfdIndexSelect -h $EXPLOR_AREA/Data/Istex/Checkpoint/KwdEn.i -k "neuroprotection"
HfdIndexSelect -h $EXPLOR_AREA/Data/Istex/Checkpoint/KwdEn.i \
-Sk "neuroprotection" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Istex/Checkpoint/biblio.hfd
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Checkpoint
|type= indexItem
|index= KwdEn.i
|clé= neuroprotection
}}
| This area was generated with Dilib version V0.6.23. Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024 | ![](Common/icons/LogoDilib.gif) |